ES2323864T3 - Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental. - Google Patents

Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental. Download PDF

Info

Publication number
ES2323864T3
ES2323864T3 ES04001937T ES04001937T ES2323864T3 ES 2323864 T3 ES2323864 T3 ES 2323864T3 ES 04001937 T ES04001937 T ES 04001937T ES 04001937 T ES04001937 T ES 04001937T ES 2323864 T3 ES2323864 T3 ES 2323864T3
Authority
ES
Spain
Prior art keywords
mental fatigue
relief
potential
complexes
cognitive functions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04001937T
Other languages
English (en)
Inventor
Paolo Morazzoni
Orlando Petrini
Andrew Scholey
David Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Application granted granted Critical
Publication of ES2323864T3 publication Critical patent/ES2323864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de complejos lipófilos solubles en disolventes non-polares y apróticos, dichos complejos consisten en: - un extracto de Ginkgo biloba que contiene al menos 20% de glicósidos de flavona de Ginkgo biloba y 2 a 10% de terpeno lactonas y - un fosfolípido que contiene entre 10 y 50% de fosfatidilserina para la fabricación de un medicamento para el tratamiento y prevención de una enfermedad relacionada con la reducción de la función cognitiva y fatiga mental.
ES04001937T 2004-01-29 2004-01-29 Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental. Expired - Lifetime ES2323864T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04001937A EP1559430B1 (en) 2004-01-29 2004-01-29 Use of ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue

Publications (1)

Publication Number Publication Date
ES2323864T3 true ES2323864T3 (es) 2009-07-27

Family

ID=34639409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04001937T Expired - Lifetime ES2323864T3 (es) 2004-01-29 2004-01-29 Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental.

Country Status (20)

Country Link
US (1) US8591965B2 (es)
EP (1) EP1559430B1 (es)
JP (1) JP5300196B2 (es)
KR (2) KR101249633B1 (es)
CN (1) CN1913907B (es)
AT (1) ATE428312T1 (es)
AU (1) AU2005210091B2 (es)
CA (1) CA2554760C (es)
DE (1) DE602004020574D1 (es)
DK (1) DK1559430T3 (es)
ES (1) ES2323864T3 (es)
HK (1) HK1098380A1 (es)
IL (1) IL177118A (es)
NO (1) NO331190B1 (es)
PL (1) PL219337B1 (es)
PT (1) PT1559430E (es)
RU (1) RU2368385C2 (es)
SG (1) SG172727A1 (es)
SI (1) SI1559430T1 (es)
WO (1) WO2005074956A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100723609B1 (ko) * 2006-04-28 2007-06-04 주식회사 유유 신규한 조성의 알츠하이머형 치매 및 파킨슨씨병 예방 또는 치료용 은행잎 추출물, 그리고 은행잎으로부터의 추출 및 정제 방법
EP3446696A1 (de) * 2007-12-21 2019-02-27 Dr. Willmar Schwabe GmbH & Co. KG Verwendung eines extraktes aus blättern von ginkgo biloba
ITTO20080532A1 (it) * 2008-07-10 2010-01-11 Euro Pharma S R L Integratore dietetico atto al potenziamento neuronale e sensoriale
IT1397386B1 (it) * 2010-01-12 2013-01-10 Indena Spa Composizioni a base di estratti di andrographis paniculata combinati con estratti di ginkgo biloba complessati con fosfolipidi e loro uso.
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN103156022B (zh) * 2011-12-09 2014-12-17 四川科伦药物研究有限公司 一种银杏叶保健茶及其制备方法
CA2967895C (en) * 2014-11-20 2021-09-07 Enzymotec Ltd. Phospholipid preparations for the improvement of communication skills
JP6923940B2 (ja) 2016-04-15 2021-08-25 慶裕 広川 認知機能改善剤
CN105901649A (zh) * 2016-05-03 2016-08-31 王胜 一种含银杏提取物的植物盐及其制备方法
RU2680809C2 (ru) * 2016-12-20 2019-02-27 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ получения наноразмерной фитосомальной системы
US20200226948A1 (en) * 2019-01-14 2020-07-16 Robert Warren Time and Attention Evaluation System
BR112022013296A2 (pt) * 2020-01-03 2022-09-06 Biosearch S A Composição para uso no tratamento de transtornos cognitivos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2929959A1 (de) * 1979-07-24 1981-02-19 Hoechst Ag Thermoplastische kunststoffmasse
IT1201149B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
IT1238684B (it) * 1990-02-09 1993-09-01 Indena Spa Derivati del bilobalide,loro usi e formulazioni che li contegono
DE60009145T3 (de) * 1999-12-17 2010-02-25 Pharmaton S.A. Zusammensetzung von ginseng und ginkgo zur verbesserung von kognitivem vermögen
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
KR20020069539A (ko) * 2001-02-26 2002-09-05 주식회사 두산 뇌세포 보호용 조성물
EP1414469A2 (de) * 2001-08-09 2004-05-06 Degussa Food Ingredient GmbH Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern
JP2003169632A (ja) * 2001-12-08 2003-06-17 Sapuri:Kk 米胚芽油、卵黄油及びホスファチジルセリン含有の健康食品
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
US6572899B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation

Also Published As

Publication number Publication date
US20080226757A1 (en) 2008-09-18
SG172727A1 (en) 2011-07-28
JP2007519668A (ja) 2007-07-19
EP1559430B1 (en) 2009-04-15
NO20063463L (no) 2006-07-27
US8591965B2 (en) 2013-11-26
KR101249667B1 (ko) 2013-04-02
KR20060130148A (ko) 2006-12-18
AU2005210091B2 (en) 2010-06-03
IL177118A (en) 2011-03-31
HK1098380A1 (en) 2007-07-20
AU2005210091A1 (en) 2005-08-18
DK1559430T3 (da) 2009-07-20
SI1559430T1 (sl) 2009-08-31
WO2005074956A1 (en) 2005-08-18
PL380826A1 (pl) 2007-03-19
RU2006127272A (ru) 2008-02-10
DE602004020574D1 (de) 2009-05-28
JP5300196B2 (ja) 2013-09-25
KR101249633B1 (ko) 2013-04-02
RU2368385C2 (ru) 2009-09-27
CA2554760C (en) 2018-10-09
PT1559430E (pt) 2009-06-16
CA2554760A1 (en) 2005-08-18
KR20110123289A (ko) 2011-11-14
IL177118A0 (en) 2008-03-20
PL219337B1 (pl) 2015-04-30
ATE428312T1 (de) 2009-05-15
NO331190B1 (no) 2011-10-31
CN1913907A (zh) 2007-02-14
EP1559430A1 (en) 2005-08-03
CN1913907B (zh) 2011-03-30

Similar Documents

Publication Publication Date Title
ES2323864T3 (es) Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental.
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
GT200500378A (es) Macrolidos
CO5660275A2 (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
RS52651B (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROPHOLATE
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
UY27186A1 (es) Formulación farmacéutica
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
HK1091123A1 (en) Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
AR046642A1 (es) Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
SI1392335T1 (sl) Farmacevtski in/ali kozmetiäśni sestavki za oskrbo lokalizirane adipoznosti in celulita
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso
ES2195939T3 (es) Composicion para prevencion y/o tratamiento de trastornos circulatorios que comprende derivados de l-carnitina y extractos de ginkgo biloba.
AR008506A1 (es) Composicion farmaceutica.